Literature DB >> 23159297

Limitations in qualitative point of care hCG tests for detecting early pregnancy.

Dina N Greene1, Robert L Schmidt, Sandy M Kamer, David G Grenache, Carolyn Hoke, Thomas S Lorey.   

Abstract

BACKGROUND: Detection of early pregnancy in the healthcare setting is important for proper patient management. Qualitative point-of-care (POC) human chorionic gonadotropin (hCG) testing is often used. There is a gap in the literature for evaluating patient samples with low (<300 IU/l) hCG concentration using POC devices.
METHODS: Specimens (urine, n=289; serum, n=269) with hCG concentrations between 2 and >5000 IU/l were evaluated by hCG POC testing. Approximately half of these had an hCG concentration<300 IU/l. All specimens were evaluated using the OSOM and QuickVue+ POC hCG devices. Pregnancy status was evaluated by patient chart review.
RESULTS: The OSOM and QuickVue+ devices were able to detect hCG in 53% (OSOM) and 78% (QuickVue+) of urine samples with an hCG concentration range between 20 and 300 IU/l. Serum samples with an hCG concentration range between 10 and 300 IU/l gave positive results in 79 and 91% of samples tested using the OSOM and QuickVue+, respectively. False negative results could not be attributed to the high-dose hook effect, the hCG variant effect, or the interpreters' evaluation. The mean gestational age for specimens corresponding to the false negative results was 4 weeks.
CONCLUSIONS: The sensitivity of 2 commonly used hCG POC devices is insufficient for detecting very early pregnancy.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23159297     DOI: 10.1016/j.cca.2012.10.053

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Negative urine pregnancy test in a molar pregnancy: is it possible?

Authors:  Aruna Nigam; Archana Kumari; Nidhi Gupta
Journal:  BMJ Case Rep       Date:  2014-11-05

2.  Analytical and clinical validation of the Immulite 1000 hCG assay for quantitative analysis in urine.

Authors:  Frances L Cate; Courtney Moffett; Ann M Gronowski; David G Grenache; Katherine E Hartmann; Alison Woodworth
Journal:  Clin Chim Acta       Date:  2013-03-05       Impact factor: 3.786

3.  Optimization of Patient Management in the Gynecology Emergency Department Using Point-of-Care Beta hCG.

Authors:  Mehdi Brousse; Anne-Sophie Bargnoux; Caroline Courtais-Coulon; Stéphanie Badiou; Nils Kuster; Clara Compan; Florent Fuchs; Jean-Paul Cristol
Journal:  Diagnostics (Basel)       Date:  2022-07-09

4.  A Point-of-Care Immunosensor for Human Chorionic Gonadotropin in Clinical Urine Samples Using a Cuneated Polysilicon Nanogap Lab-on-Chip.

Authors:  S R Balakrishnan; U Hashim; Subash C B Gopinath; P Poopalan; H R Ramayya; M Iqbal Omar; R Haarindraprasad; P Veeradasan
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

5.  Flotation Immunoassay: Masking the Signal from Free Reporters in Sandwich Immunoassays.

Authors:  Hui Chen; Anna E V Hagström; Jinsu Kim; Gavin Garvey; Andrew Paterson; Federico Ruiz-Ruiz; Balakrishnan Raja; Ulrich Strych; Marco Rito-Palomares; Katerina Kourentzi; Jacinta C Conrad; Robert L Atmar; Richard C Willson
Journal:  Sci Rep       Date:  2016-04-14       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.